Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism

NCT00397059 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Healthy

Interventions

DRUG: Escitalopram

Sponsor

University of Southern Denmark

Collaborators

[object Object]